You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

High-Risk MDS

Showing 51 - 75 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

AML and High Risk MDS Trial in Worldwide (LGH447, LGH447 + midostaurin)

Completed
  • AML and High Risk MDS
  • Ann Arbor, Michigan
  • +8 more
Dec 16, 2020

Acute Myelogenous Leukemia, Myelodysplastic Syndrome Trial in United States (Milademetan, AZA)

Terminated
Has Results
  • Acute Myelogenous Leukemia
  • Myelodysplastic Syndrome
  • Duarte, California
  • +4 more
Sep 14, 2021

Azacitidine in International Prognostic Scoring System

Recruiting
  • Myelodysplastic Syndromes
  • +2 more
    • Hefei, Anhui, China
    • +16 more
    Sep 6, 2022

    Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS Trial in Washington, Baltimore (Tumor associated

    Recruiting
    • Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS
    • Tumor associated antigen lymphocytes (TAA-T)
    • Washington, District of Columbia
    • +1 more
    Jul 15, 2021

    MDS/MPN Trial in Nanjing (Azacitidine (AZA) with Ruxolitinib)

    Recruiting
    • MDS/MPN
    • Azacitidine (AZA) with Ruxolitinib
    • Nanjing, Jiangsu, China
      The First Affiliated Hospital of Nanjing Medical University
    Apr 17, 2023

    Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R Trial in Canada, United States (Etavopivat)

    Recruiting
    • Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
    • Ocala, Florida
    • +3 more
    Jan 30, 2023

    Acute Myeloid Leukaemia, Myelodysplasia Trial in Birmingham (Vyxeos, Fludarabine, Busulphan)

    Recruiting
    • Acute Myeloid Leukaemia
    • Myelodysplasia
    • Birmingham, United Kingdom
      Queen Elizabeth Hospital
    Oct 14, 2021

    MDS Trial (Roxadustat in combination with retinoic acid)

    Not yet recruiting
    • Myelodysplastic Syndromes
    • Roxadustat in combination with retinoic acid
    • (no location specified)
    Aug 26, 2023

    Myelodysplastic Syndrome (MDS) Trial in United States (AMV564 14-Day CIV)

    Completed
    • Myelodysplastic Syndrome (MDS)
    • AMV564 14-Day CIV
    • Duarte, California
    • +4 more
    Oct 11, 2021

    Acute Myelogenous Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Chronic Myelogenous Leukemia (CML) Trial in United States

    Recruiting
    • Acute Myelogenous Leukemia (AML)
    • +5 more
    • Conditioning Chemotherapy
    • Cord blood graft
    • Basking Ridge, New Jersey
    • +6 more
    May 22, 2023

    Acute Myelogenous Leukemia, MDS Trial in Petach Tikva, Re?ovot (Nerofe, Doxorubicin)

    Withdrawn
    • Acute Myelogenous Leukemia
    • Myelodysplastic Syndromes
    • Petach Tikva, Israel
    • +1 more
    Jul 29, 2020

    MDS, Myeloproliferative Tumor, Anemia Trial in Tampa (Luspatercept)

    Recruiting
    • Myelodysplastic Syndromes
    • +2 more
    • Tampa, Florida
      Moffitt Cancer Center
    Feb 16, 2023

    MDS Trial in Houston (Luspatercept)

    Not yet recruiting
    • Myelodysplastic Syndromes
    • Houston, Texas
      M D Anderson Cancer Center
    Nov 2, 2023

    MDS Trial run by the National Cancer Institute (NCI) (KPT-8602, Inqovi)

    Not yet recruiting
    • Myelodysplastic Syndromes
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jun 30, 2023

    Patients With MDS, Acute Myeloid Leukemia (AML) Evolving From MDS, and Chronic Myelomonocytic Leukemia (CMML) Trial in Seoul

    Active, not recruiting
    • Patients With MDS, Acute Myeloid Leukemia (AML) Evolving From MDS, and Chronic Myelomonocytic Leukemia (CMML)
    • Seoul, Korea, Republic of
      Asan Medical Center, University of Ulsan College of Medicine
    Oct 19, 2023

    Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid

    Recruiting
    • Acute Lymphoblastic Leukemia in Remission
    • +11 more
    • Astatine At 211 Anti-CD45 Monoclonal Antibody BC8-B10
    • +8 more
    • Seattle, Washington
      Fred Hutch/University of Washington Cancer Consortium
    Oct 24, 2022

    MDS Patients Using Sequential Peripheral Blood Samples

    Recruiting
    • Myelodysplastic Syndromes
      • Badalona, Barcelona, Spain
        Josep Carreras Leukaemia Research Institute
      Mar 8, 2022

      Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia

      Recruiting
      • Acute Lymphoblastic Leukemia
      • +11 more
      • Seattle, Washington
        Fred Hutch/University of Washington Cancer Consortium
      Aug 29, 2022

      Lower Risk MDS Per IPSS-R Trial (Luspatercept)

      Not yet recruiting
      • Lower Risk MDS Per IPSS-R
      • (no location specified)
      Jun 21, 2023

      Lower-risk Myelodysplastic Syndrome Trial in Tampa (JSP191)

      Recruiting
      • Lower-risk Myelodysplastic Syndrome
      • Tampa, Florida
        Moffitt Cancer Center
      Jun 20, 2023

      Myelodysplastic Syndromes Not Candidates for Allogeneic

      Unknown status
      • Myelodysplastic Syndromes
      • Azacitidine Injection [Vidaza]
      • Palma, Islas Baleares, Spain
        Son Llàtzer
      Oct 20, 2020

      MDS Over Time - Comparison of Treated vs Untreated Patients

      Completed
      • Myelodysplastic Syndromes
        • Vienna, Austria
          Hanusch Krankenhaus, 3.Medizinische Abteilung
        Nov 21, 2022

        Lower-risk MDS Patients

        Recruiting
        • MDS
          • Leipzig, Germany
            University Hospital Leipzig
          Oct 13, 2022

          MDS Trial in Seoul (cyclophosphamide, fludarabine, and antithymocyte globulin)

          Active, not recruiting
          • Myelodysplastic Syndromes
          • cyclophosphamide, fludarabine, and antithymocyte globulin
          • Seoul, Korea, Republic of
            Asan Medical Center, University of Ulsan College of Medicine
          Oct 19, 2023

          MDS Trial in Beijing (Hetrombopag, Stanozolol Tablets)

          Not yet recruiting
          • MDS
          • Beijing, China
            Peking Union Medical College Hospital
          Sep 18, 2021